论文部分内容阅读
目的:回顾性分析国产培美曲塞二钠单药治疗晚期复发肺腺癌患者的临床疗效及耐受性。方法:54例经组织学或细胞学确诊的晚期肺腺癌患者,均经既往治疗失败,采用国产培美曲塞单药化疗,方案为培美曲塞500mg.m-2,d 1,ivgtt,每3周重复,均按照说明书口服地塞米松、叶酸并肌内注射维生素B12以减轻不良反应,完成2个周期以上化疗后评价疗效和不良反应。结果:54例患者均接受2个周期以上的治疗,全组无完全缓解(CR)病例,部分缓解(PR)7例,疾病稳定(SD)26例,疾病进展(PD)21例,有效率(CR+PR)为13.0%(7/54),疾病控制率(DCR)为61.1%(33/54),中位无疾病进展时间(PFS)3个月。不良反应主要为Ⅰ/Ⅱ度骨髓抑制、胃肠道反应及乏力,无治疗相关性死亡病例,亦无因不良反应中断治疗的病例。结论:国产培美曲塞单药治疗晚期复发肺腺癌疗效确切,耐受性较好。
Objective: To retrospectively analyze the clinical efficacy and tolerability of domestic pemetrexed disodium monotherapy in patients with advanced recurrent lung adenocarcinoma. Methods: Totally 54 patients with advanced lung adenocarcinoma diagnosed by histology or cytology were treated with domestic pemetrexed single-agent chemotherapy after previous treatment failure. The protocol was pemetrexed 500 mg.m-2, d 1, ivgtt , Repeated every 3 weeks, according to the instructions of oral dexamethasone, folic acid and intramuscular injection of vitamin B12 to reduce adverse reactions, to complete the 2 cycles after chemotherapy to evaluate the efficacy and adverse reactions. Results: All of the 54 patients received more than 2 cycles of treatment. There were 7 cases of complete remission (CR), 7 cases of partial remission (PR), 26 cases of stable disease (SD) and 21 cases of disease progression (PD) (CRR) was 13.0% (7/54). The disease control rate (DCR) was 61.1% (33/54), and the median progression-free time (PFS) was 3 months. Adverse reactions mainly Ⅰ / Ⅱ degree of myelosuppression, gastrointestinal reactions and fatigue, no treatment-related deaths, no cases of adverse reactions due to interruption of treatment. Conclusion: The domestic pemetrexed monotherapy for the treatment of advanced recurrent lung adenocarcinoma is effective and well tolerated.